Colin Foster

Executive Chairman | Cytosolix, Inc.

Colin has thirty years of experience as Chairman, Executive Chairman, Board Member, CEO, entrepreneur, and investor in public and private life science companies, with leadership across the R&D–manufacturing–commercial continuum in therapeutics, diagnostics, medical devices, and OTC consumer healthcare. As CEO he has led multi-billion-dollar, mid-sized, and start-up companies and divisions in the USA, Canada, Israel, and the UK/Ireland. He is Co-founder, Chairman & CEO of Cytosolix, a venture-backed oncology company founded on technology from Yale, and Co-founder & Chairman of Saatient Therapeutics, an oncology company spun out of Columbia. He sits on the board of NBO Pharma and chairs its Compensation Committee, serves on Columbia's Irving Cancer Drug Discovery Advisory Board and the NYU Langone Health's Investment Advisory Committee, and is an Entrepreneur-in-Residence at Yale. Previously, he was CEO of iSci Management, CEO of Bioblast Pharma (NASDAQ), Executive Chairman of Ivenix, and Co-founder & CEO of Optherion. Earlier, over ten years at Bayer, he rose to President & CEO of Bayer Pharmaceuticals Corporation USA and Region Head of the North American Pharmaceuticals Group and was a member of Bayer AG’s Global Pharmaceutical Operating Committee. Colin holds a B.Sc. from the University of Toronto and an M.B.A. from Ivey Business School at Western University. He is a citizen of Canada, the USA, and the UK.